

January 27, 2023

Hexagon Nutrition Limited: Ratings reaffirmed; rated amount enhanced

Summary of rating action

Instrument*	Previous Rated Amount (Rs. crore)	Current Rated Amount (Rs. crore)	Rating Action
Long-term, Fund-based Limit– Cash Credit	4.00	4.00	[ICRA]A- (Stable); reaffirmed
Long-term, Fund-based Limit– Term Loans	4.00	9.00	[ICRA]A- (Stable); reaffirmed/ assigned
Short-term, Fund-based Limit	19.00	29.00	[ICRA]A2+; reaffirmed/assigned
Short-term, Non-fund Based Limit	(3.00)**	(3.00)**	[ICRA]A2+; reaffirmed
Unallocated Amount	5.00	5.00	[ICRA]A- (Stable)/[ICRA]A2+; reaffirmed
Total	32.00	47.00	

*Instrument details are provided in Annexure-I

**Sublimit of cash credit

Rationale

To arrive at the ratings, ICRA has consolidated the business and financial risk profiles of Hexagon Nutrition Limited (HNL), and its subsidiaries including, Hexagon Nutrition (Exports) Private Limited (HNEPL) and Hexagon Nutrition (International) Private Limited (HNIPL), together referred to as the Hexagon Group. ICRA has noted the common management, close financial and operational linkages between these entities while arriving at the ratings.

The reaffirmation of the ratings of Hexagon Group factor in its established business position and the extensive experience of its promoters in the nutraceutical and dietary supplements segment, as well as its affiliation with reputed international organisations like Global Alliance for Improved Nutrition (GAIN), United Nations Children’s Fund (UNICEF) and the World Food Programme (WFP) of the United Nations. The ratings also favourably factor in the rising demand for nutraceuticals across the globe with an increased focus on addressing malnutrition in developing and underdeveloped countries across the world. This has contributed to the growth in the Group’s revenue to Rs. 273.3 crore in FY2022 from Rs. 213.8 crore in FY2021. However, the revenue growth momentum has moderated in H1 FY2023 due to considerably low contribution from the Environments, Social and Governance (ESG) segment. Nevertheless, the same has picked up in recent months and is expected to scale up considerably in FY2024, supported by healthy order inflow from WFP and UNICEF.

Additionally, the ratings derive comfort from the Group’s comfortable capitalisation and debt coverage indicators along with its adequate liquidity position. HNL was net debt negative at a consolidated level with total debt of ~Rs. 42 crore as on March 31, 2022, against total cash/liquid investments of ~Rs. 51 crore.

However, the ratings are constrained by the Group’s moderate scale of operations in an intensely competitive dietary supplements and nutraceutical segment comprising large, established players as well as various small, unorganised players. Also, the Group’s profitability remains vulnerable to volatility in raw material prices and foreign currency exchange rates. This is also demonstrated by the decline in operating margins over FY2022 and H1 FY2023. Despite some expected improvement in H2 FY2023, operating margins are likely to remain considerably lower than the previous fiscal. Though with the stabilisation of raw material prices and healthy anticipated revenue growth, operating margins are expected to improve sequentially in FY2024. Further, any material impact on the Group’s credit profile or liquidity position, arising from the event of exit of the private equity (PE) investor over the near term, will be a key rating monitorable.

The Stable outlook on HNL's long-term rating reflects ICRA's expectation that the Group will continue to witness a steady growth in revenues backed by the rising demand for nutraceutical and branded dietary supplements across the globe while maintaining a comfortable credit profile with adequate liquidity.

Key rating drivers and their description

Credit strengths

Extensive experience of the promoters in micronutrient premixes and dietary supplements – HNL is a part of the Mumbai-based Hexagon Group established in 1993 by Mr. Arun Kelkar and family. It has been in the business of manufacturing micronutrient premixes and dietary supplements ever since. The promoters are professionally qualified in their field of operations and have prior experience of working with multinational FMCG companies.

Affiliation with international organisations like GAIN and WFP – HNL is one of the 44 premix blenders in the world selected by GAIN under its GAIN Premix Facility (GPF) initiative. The company partners with WFP and other international NGOs in supplying them with vitamin and mineral premixes for their food fortification initiatives in developing and underdeveloped nations. It is also one of the 22 companies across the globe approved by UNICEF and WFP for procurement of ready-to-use therapeutic food (RUTF) and micronutrient powders (MNP). In recent months, the Group has received healthy orders from these agencies, which is expected to support its revenue growth, going forward.

Comfortable capitalisation and debt coverage indicators; adequate liquidity position – Steady internal accrual generation and no major increase in debt levels has continued to result in comfortable capitalisation and debt coverage indicators for the Group, with gearing of 0.3 time as on March 31, 2022, and total debt/OPBDITA of 1.1 times, Net debt/OPBDITA of (0.2) time and interest coverage of 17.4 times in FY2022. Additionally, the Group's liquidity profile remains adequate supported by steady internal accrual generation, cash/liquid investments and undrawn bank lines.

Rising demand for immunity-boosting products with changing lifestyles, coupled with expansion into overseas markets and UNICEF certification to help expand revenue base over the near to medium term – The receipt of the UNICEF certification and the rising demand for nutritional products in the domestic and export markets in the wake of changing lifestyle preferences of mass consumers is expected to drive the Group's revenue in the near to medium term. Further, the increasing focus of various governments, international agencies, and NGOs towards addressing malnutrition across the globe is expected to support revenue growth. The Group commissioned its manufacturing facility in Uzbekistan in May 2022 and has registered healthy growth in this market within a short span of time.

Credit challenges

Moderate scale of operations – Despite healthy growth in FY2022, the Group's scale of operations remained moderate at Rs. 273.3 crore in FY2022 and is expected to remain at similar levels in FY2023 as well. Revenue growth in the current fiscal has been relatively muted due to considerably low contribution from the ESG segment in H1 FY2023. However, the same has picked up in H2 FY2023 and is expected to scale up considerably over the near term, supported by a healthy order book. The Group is one of the largest players in India in the premix manufacturing segment; however, its presence in the dietary supplements space remains limited in a competitive market with several large players like Abbott Nutrition, Nestle Health Science, and Hindustan Unilever, etc, and many smaller, unorganised players. HNL's ability to grow its branded dietary supplements remain one of the key monitorables for the growth of the company.

Vulnerability of profitability to fluctuations in raw material prices and forex rates; stiff competition in dietary supplements and nutraceutical segments – The primary raw materials for the manufacturing of nutraceuticals are vitamins, minerals, whey protein and skim milk powder (SMP). The Hexagon Group's profit margins remain vulnerable to the volatility in the prices of these key raw materials, given the fixed price nature of most of its contracts and high competitive intensity of the industry. This is also demonstrated by the decline in operating margins over FY2022 and H1 FY2023. Despite some expected

improvement in H2 FY2023, operating margins are likely to remain considerably lower than the previous fiscal. However operating margins are expected to improve in FY2024 on the back of some stabilisation in raw material prices and healthy anticipated revenue growth. The Group is a net exporter with overall net exports of Rs. 25-30 crores per annum over the past few years. Therefore, it is exposed to foreign exchange risks to the extent not covered by natural hedge due to its imports and exports.

Potential liability on HNL to provide exit to PE investor in the absence of an IPO may impact cash flow position – As per the term sheet signed with the PE investor, the Group was scheduled to provide it with an exit by November 2022 and, accordingly, HNL had filed its DRHP (valid till March 2023) for an IPO. However, in case of its inability to come out with an IPO by then, the Group will have to evaluate other options to provide an exit to the PE investor. Any material liability or cash outflow to facilitate the same, impacting the Group's credit profile and liquidity position will remain a key monitorable.

Liquidity position: Adequate

The Hexagon Group's liquidity position remains **adequate**, supported by steady internal accrual generation, healthy unencumbered cash balance and liquid investments of ~Rs. 47.0 crore as on December 15, 2022, and cushion in the form of undrawn working capital limits of around Rs. 10 crore. Additionally, the Group does not have any major debt-funded capex plans over the near term and moderate debt repayment of up to Rs. 3 crore p.a. over FY2023-FY2024, which will further support its liquidity profile.

Rating sensitivities

Positive factors – Substantial increase in scale and profitability, along with improvement in working capital intensity will be key for a higher rating.

Negative factors – Decline in profitability or any higher than-anticipated debt-funded capex, or a stretch in the working capital cycle weakens the liquidity position. Any material liability following the exit of the PE investor leading to weakening of its cash flows may also adversely impact the ratings. Specific credit metrics include Total Debt/OPBDITA over 2.0 times on a sustained basis.

Analytical approach

Analytical Approach	Comments
Applicable rating methodologies	Corporate Credit Rating Methodology Rating Methodology for Entities in the Pharmaceutical Industry
Parent/Group support	Not Applicable
Consolidation/Standalone	The rating is based on the consolidated financial statements of HNL

About the company

Hexagon Nutrition Limited, incorporated in 1993 by Mr. Arun Kelkar and family, is the flagship company of the Mumbai-based Hexagon Group. The Group manufactures and sells micronutrient premixes for human as well as veterinary consumption, along with therapeutic food and dietary supplements (branded products). The Group, besides domestic sales, also exports its vitamin and mineral premixes to more than 70 countries, primarily through its collaborations with WFP, GAIN, other international organisations, and NGOs.

The Group's manufacturing facilities are at Nashik (under HNL in Maharashtra, catering to domestic and export markets), Chennai (in MEPZ3 SEZ, under HNEPL, catering to export markets) and Tuticorin (in the Food Processing Zone of Pearl City Food Port SEZ, Tamil Nadu, under HNIPL, catering mainly to export markets) and Uzbekistan (under a foreign subsidiary, Hexagon

Nutrition Limited Liability Company). The domestic manufacturing facilities are ISO 22000:2005, Food Safety System Certification (FSSC) 22000:2010, GMP Australia and Halal certified. HNL also has a food testing laboratory-cum-research center in Nashik.

Key financial indicators (audited)

HNL – Consolidated	FY2021	FY2022
Operating Income (Rs. crore)	213.8	273.3
PAT (Rs. crore)	22.9	23.3
OPBDIT/OI (%)	17.9%	14.6%
PAT/OI (%)	10.7%	8.5%
Total Outside Liabilities/Tangible Net Worth (times)	0.5	0.6
Total Debt/OPBDIT (times)	0.5	1.0
Interest Coverage (times)	14.8	17.4

PAT: Profit After Tax; OPBDITA: Operating Profit Before Depreciation, Interest, Taxes and Amortisation

Source: Company, ICRA Research; All ratios as per ICRA calculations

HNL – Standalone	FY2021	FY2022
Operating Income (Rs. crore)	87.1	106.7
PAT (Rs. crore)	5.7	8.9
OPBDIT/OI (%)	9.8%	12.8%
PAT/OI (%)	6.6%	8.4%
Total Outside Liabilities/Tangible Net Worth (times)	0.6	0.7
Total Debt/OPBDIT (times)	1.5	1.6
Interest Coverage (times)	9.2	19.2

PAT: Profit After Tax; OPBDITA: Operating Profit Before Depreciation, Interest, Taxes and Amortisation

Source: Company, ICRA Research; All ratios as per ICRA calculations

Status of non-cooperation with previous CRA: Not applicable

Any other information: None

Rating history for past three years

Instrument		Current rating (FY2023)				Chronology of rating history for the past 3 years			
		Type	Amount rated (Rs. crore)	Amount outstanding as of Oct 31, 2022 (Rs. crore)	Date & rating in FY2023	Date & rating in FY2022	Date & rating in FY2021	Date & rating in FY2020	
					Jan 27, 2023	Oct 27, 2021	Aug 25, 2020	Mar 03, 2020	
1	Term loan	Long-term	9.00	2.11	[ICRA]A-(Stable)	[ICRA]A-(Stable)	[ICRA]BBB+ (Positive)	[ICRA]BBB+(Stable)	
2	Cash Credit	Long-term	4.00	-	[ICRA]A-(Stable)	[ICRA]A-(Stable)	[ICRA]BBB+ (Positive)	[ICRA]BBB+(Stable)	

3	PCFC	Short-term	29.00	-	[ICRA]A2+	[ICRA]A2+	[ICRA]A2	[ICRA]A2
4	LC/BG*	Short-term	(3.00)	-	[ICRA]A2+	[ICRA]A2+	[ICRA]A2	[ICRA]A2
5	Unallocated	Long-term and Short-term	5.00	-	[ICRA]A-(Stable)/ [ICRA]A2+	[ICRA]A-(Stable)/ [ICRA]A2+	-	-

*Sublimit of cash credit

Complexity level of the rated instruments

Instrument	Complexity Indicator
Long-term Fund based - Term loan	Simple
Long-term Fund based - Cash Credit	Simple
Short-term Fund based – Packing credit	Simple
Short-term non-fund-based-Letter of Credit/ Bank Guarantee	Very Simple
Unallocated	Not Applicable

The Complexity Indicator refers to the ease with which the returns associated with the rated instrument could be estimated. It does not indicate the risk related to the timely payments on the instrument, which is rather indicated by the instrument's credit rating. It also does not indicate the complexity associated with analysing an entity's financial, business, industry risks or complexity related to the structural, transactional or legal aspects. Details on the complexity levels of the instruments are available on ICRA's website: [Click Here](#)

Annexure I: Instrument details

ISIN	Instrument Name	Date of Issuance	Coupon Rate	Maturity	Amount Rated (Rs. crore)	Current Rating and Outlook
NA	Term loan	FY2014	8.5%	FY2024	4.00	[ICRA]A-(Stable)
NA	Term loan	FY2023	8.5%	FY2028	5.00	[ICRA]A-(Stable)
NA	Cash Credit	-	-	-	4.00	[ICRA]A-(Stable)
NA	PCFC	-	-	-	27.00	[ICRA]A2+
NA	PCFC	-	-	-	2.00	[ICRA]A2+
NA	LC/BG	-	-	-	(3.00) *	[ICRA]A2+
NA	Unallocated	-	-	-	5.00	[ICRA]A-(Stable)/ [ICRA]A2+

Source: Company; * Sublimit of cash credit

[Please click here to view details of lender-wise facilities rated by ICRA](#)

Annexure II: List of entities considered for consolidated analysis

Company Name	HNL Ownership	Consolidation Approach
Hexagon Nutrition Limited	100.00% (rated entity)	Full Consolidation
Hexagon Nutrition (Exports) Private Limited	100.00%	Full Consolidation
Hexagon Nutrition (International) Private Limited	100.00%	Full Consolidation
Nutralytica Research Private Limited*	100.00%	Full Consolidation
Hexagon Nutrition Healthcare Pvt. Ltd.	100.00%	Full Consolidation
Hexagon Nutrition (PTY) Ltd.	100.00%	Full Consolidation
Hexagon Nutrition LLC	100.00%	Full Consolidation
Hexagon Nutrition China Ltd.	100.00%	Full Consolidation

Source: HNL annual report FY2022

Note: ICRA has taken a consolidated view of the parent (HNL), its subsidiaries while assigning the ratings.

*Nutralytica Research Private Limited is merged with HNL vide order dated October 4, 2022

ANALYST CONTACTS

Shamsher Dewan

+91 124 4545328

shamsherd@icraindia.com

Kinjal Shah

+91 022 61143400

kinjal.shah@icraindia.com

Deepak Jotwani

+91 4545 870124

deepak.jotwani@icraindia.com

Gaurav Kushwaha

+91 22 61143465

gaurav.kushwaha@icraindia.com

RELATIONSHIP CONTACT

Jayanta Chatterjee

+91 80 4332 6401

jayantac@icraindia.com

MEDIA AND PUBLIC RELATIONS CONTACT

Ms. Naznin Prodhani

Tel: +91 124 4545 860

communications@icraindia.com

Helpline for business queries

+91-9354738909 (open Monday to Friday, from 9:30 am to 6 pm)

info@icraindia.com

About ICRA Limited:

ICRA Limited was set up in 1991 by leading financial/investment institutions, commercial banks and financial services companies as an independent and professional investment Information and Credit Rating Agency.

Today, ICRA and its subsidiaries together form the ICRA Group of Companies (Group ICRA). ICRA is a Public Limited Company, with its shares listed on the Bombay Stock Exchange and the National Stock Exchange. The international Credit Rating Agency Moody's Investors Service is ICRA's largest shareholder.

For more information, visit www.icra.in

ICRA Limited



Registered Office

B-710, Statesman House, 148, Barakhamba Road, New Delhi-110001
Tel: +91 11 23357940-45



Branches



© Copyright, 2023 ICRA Limited. All Rights Reserved.

Contents may be used freely with due acknowledgement to ICRA.

ICRA ratings should not be treated as recommendation to buy, sell or hold the rated debt instruments. ICRA ratings are subject to a process of surveillance, which may lead to revision in ratings. An ICRA rating is a symbolic indicator of ICRA's current opinion on the relative capability of the issuer concerned to timely service debts and obligations, with reference to the instrument rated. Please visit our website www.icra.in or contact any ICRA office for the latest information on ICRA ratings outstanding. All information contained herein has been obtained by ICRA from sources believed by it to be accurate and reliable, including the rated issuer. ICRA however has not conducted any audit of the rated issuer or of the information provided by it. While reasonable care has been taken to ensure that the information herein is true, such information is provided 'as is' without any warranty of any kind, and ICRA in particular, makes no representation or warranty, express or implied, as to the accuracy, timeliness or completeness of any such information. Also, ICRA or any of its group companies may have provided services other than rating to the issuer rated. All information contained herein must be construed solely as statements of opinion, and ICRA shall not be liable for any losses incurred by users from any use of this publication or its contents.